AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6443576
Drug: Chronic administration
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic administration of an LHRH agonistic analogue by parenteral and/or intranasal routes
Trial: 30341003
Drug: High-dose oxytocin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oxytocin (6.6 mU/minute)
Trial: 30341003
Drug: Low-dose oxytocin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oxytocin (3.3 mU/minute)
Trial: 29408705
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (HyperBOT) at 2.5 ATA for 60 minutes
Trial: 29408705
Drug: Normobaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normobaric oxygen therapy (NormBOT) at 1.5 ATA
Trial: 24094827
Drug: Recovery with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recovery with hyperglycemia after hypoglycemia with vitamin C infusion
Trial: 11172843
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (GnRH‐a) plus tibolone (2.5 mg/d orally)
Trial: 11172843
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (GnRH‐a) plus tibolone
Trial: 11172843
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (GnRH‐a) plus placebo (1 tablet per day orally)
Trial: 8169458
Drug: Subcutaneous 200-ng
RxNorm normalized name: NG
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous 200-ng bolus of octreotide
Trial: 28536184
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g casein protein with 2 g free leucine (PRO+leu)
Trial: 28536184
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g casein protein without 2 g free leucine (PRO)
Trial: 24285757
Drug: Alvimopan (with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alvimopan (with preoperative dose)
Trial: 24285757
Drug: Alvimopan (without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alvimopan (without preoperative dose)
Trial: 18932221
Drug: Sapropterin dihydrochloride
RxNorm normalized name: Sapropterin Dihydrochloride
DrugBank: Sapropterin (DB00360)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sapropterin dihydrochloride (5, 10, or 20 mg/kg/day)
Trial: 8907720
Drug: Nefazodone (NEF)
DrugBank: Nefazodone (DB01149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nefazodone (NEF) 200 mg under fasting conditions
Trial: 8907720
Drug: Nefazodone (NEF)
DrugBank: Nefazodone (DB01149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nefazodone (NEF) 200 mg after a high‐fat breakfast
Trial: 24603072
Drug: 0.9 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 mg/kg r‐tPA
Trial: 21197501
Drug: Immediate loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate loading of single implants placed in extraction sockets
Trial: 21197501
Drug: Immediate loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate loading of single implants placed in healed ridges
Trial: 21197501
Drug: Immediate implants
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate implants (both groups)
Trial: 6111525
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of atenolol (Tenormin) for 3 days
Trial: 30447668
Drug: Intramuscular cholecalciferol
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular cholecalciferol (vitamin D)
Trial: 26829509
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of intravenous tranexamic acid
Trial: 24688085
Drug: beta‐hydroxy‐beta‐methylbutyrate/arginine/glutamine supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta‐hydroxy‐beta‐methylbutyrate/arginine/glutamine supplement (Group A)
Trial: 18551818
Drug: Cefepime (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefepime (2 g, single i.v. administration)
Trial: 18551818
Drug: Ceftriaxone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (2 g, single i.v. administration)
Trial: 15669214
Drug: Serotonin-selective reuptake
RxNorm normalized name: serotonin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serotonin-selective reuptake inhibitors (SSRIs)
Trial: 11972726
Drug: Sertraline and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline and Fluoxetine
Trial: 27522310
Drug: Bag-valve-mask device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bag-valve-mask device with oxygen at 15 L/min (BVM-15)
Trial: 27522310
Drug: Nonrebreather mask
RxNorm normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonrebreather mask with oxygen at 15 L/min (NRB-15)
Trial: 21560012
Drug: PVR >
RxNorm normalized name: Pulmonary Vascular Resistance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PVR > 100 cc at 12 months
Trial: 12766654
Drug: Bupivacaine 0.1%
RxNorm normalized name: BUPIVACAINE 0.1%/NS INJ 250ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.1% with 5 microg/ml fentanyl
Trial: 12766654
Drug: Ropivacaine 0.1%
RxNorm normalized name: ROPivacaine 0.1% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.1% with 5 microg/ml fentanyl
Trial: 11463605
Drug: UTP 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UTP 20 mg
Trial: 11463605
Drug: UTP 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UTP 100 mg
Trial: 3118327
Drug: Lactose solution
DrugBank: Lactose (DB04465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose solution (35 g)
Trial: 3118327
Drug: Glucose +
RxNorm normalized name: Fora Test N'GO Advance Blood Glucose + B-Ketone Monitoring System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose + galactose solution (17.5 + 17.5 g)
Trial: 31205105
Drug: Conventional treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatments for angina
Trial: 26241948
Drug: Peru-15 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peru-15 vaccine with buffer
Trial: 16028125
Drug: Peru-15 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peru-15 vaccine
Trial: 21196104
Drug: Fluticasone/formoterol (500/20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone/formoterol (500/20 μg, b.i.d.)
Trial: 18487565
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with carboplatin (AUC, 6) and paclitaxel (225 mg/m(2)); followed by weekly carboplatin (AUC, 2) and paclitaxel (45 mg/m(2)) with 74 Gy of TRT
Trial: 18487565
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with carboplatin (AUC, 5) and gemcitabine (1,000 mg/m(2)); followed by biweekly gemcitabine (35 mg/m(2)) with 74 Gy of TRT
Trial: 12708902
Drug: Clivarin (low-molecular-weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clivarin (low-molecular-weight heparin) administered subcutaneously at a fixed daily dosage of 1750 U
Trial: 4029877
Drug: 150 microgram
RxNorm normalized name: Norgestrel 150 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 microgram of L-thyroxine
Trial: 24578449
Drug: Perioperative glutamine
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative glutamine administration
Trial: 14578687
Drug: Bryostatin-1 25
RxNorm normalized name: Bryostatin-1
DrugBank: Bryostatin 1 (DB11752)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bryostatin-1 25 microg/m2 as a 1h infusion weekly for 3 weeks followed by a 1-week rest (Regimen I)
Trial: 14578687
Drug: Bryostatin-1 120
RxNorm normalized name: Bryostatin-1
DrugBank: Bryostatin 1 (DB11752)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bryostatin-1 120 microg/m2 as a 72 h continuous infusion every 2 weeks (Regimen II)
Trial: 8103770
Drug: Pyridostigmine (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine (120 mg, orally, at -60 min) plus GHRH (1 microgram/kg, iv, at 0 min)
Trial: 8103770
Drug: Arginine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arginine (30 g, iv, from 0-30 min) plus GHRH (1 microgram/kg, iv, at 0 min)
Trial: 29518230
Drug: Mindfulness for
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mindfulness for Pain and Performance Enhancement (MPPE) - Acceptance and Commitment Therapy-based program; six sessions over 2 weeks.
Trial: 29518230
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment services (control group); physical therapy, medical interventions, and psychoeducational groups.
Trial: 27542236
Drug: 800 IU
RxNorm normalized name: Vitamin E 800 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 IU vitamin D and 1000 mg calcium/day (tablet group)
Trial: 22954508
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (doxorubicin 75 mg/m², ifosfamide 5 g/m², lenograstim)
Trial: 22954508
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (doxorubicin, ifosfamide)
Trial: 20384716
Drug: Study drug
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study drug (new antiepileptic drugs)
Trial: 19025610
Drug: Sublingual sugar
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual sugar (SLS)
Trial: 19025610
Drug: Intravenous 10%
RxNorm normalized name: fat emulsion, intravenous 10% intravenous emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 10% glucose (IVG)
Trial: 15858602
Drug: L-carnitine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (50 mumol/kg/day, intravenously until infants tolerated 16 ml/day of feeds)
Trial: 14634414
Drug: Apomorphine hydrochloride
RxNorm normalized name: Apomorphine Hydrochloride
DrugBank: Apomorphine (DB00714)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Apomorphine hydrochloride 2 mg
Trial: 14634414
Drug: Apomorphine hydrochloride
RxNorm normalized name: Apomorphine Hydrochloride
DrugBank: Apomorphine (DB00714)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Apomorphine hydrochloride 3 mg
Trial: 14634414
Drug: Apomorphine hydrochloride
RxNorm normalized name: Apomorphine Hydrochloride
DrugBank: Apomorphine (DB00714)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Apomorphine hydrochloride (dose increased from 2 to 3 mg)
Trial: 10463681
Drug: Japanese encephalitis
RxNorm normalized name: Japanese Encephalitis IM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Japanese encephalitis vaccine (inactivated, BIKEN), administered in two dosing regimens (days 0, 7, and either 14 or 30)
Trial: 10463681
Drug: Japanese encephalitis
RxNorm normalized name: Japanese Encephalitis IM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Japanese encephalitis vaccine (inactivated, BIKEN)
Trial: 8020876
Drug: Platelet-aggregation factor
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-aggregation factor inhibitor (single doses)
Trial: 16808776
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of medical or psychosocial contraindications to outpatient treatment
Trial: 16808776
Drug: Home therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home therapy with oxygen, corticosteroids, or antibiotics before presentation
Trial: 16808776
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of one or more contraindications to outpatient treatment
Trial: 16808776
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of low-risk patients in the outpatient setting
Trial: 12774577
Drug: Five-bevel needle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five-bevel needle for subcutaneous administration
Trial: 11045835
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no cutaneous treatment)
Trial: 3304412
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg methylprednisolone (Solumedrone Upjohn Limited) given intravenously immediately preoperatively
Trial: 23103430
Drug: Group singing
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group singing training 3 times weekly for 12 weeks
Trial: 18416072
Drug: Combined use
RxNorm normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined use of acupuncture and Chinese medicines
Trial: 17021267
Drug: Oral supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral supplementation (PO)
Trial: 8872691
Drug: Intrathecal sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal sufentanil (10 micrograms) followed by 12 ml of saline
Trial: 8872691
Drug: Epidural bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural bupivacaine (12 ml of 0.25% bupivacaine)
Trial: 6288627
Drug: Guar (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guar (5 or 10 g) in aqueous solution
Trial: 6288627
Drug: Wheat bran
RxNorm normalized name: Wheat bran
DrugBank: Wheat bran (DB10685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat bran (any dosage)
Trial: 30259703
Drug: AX (astaxanthin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AX (astaxanthin 12 mg, tocotrienol 10 mg, zinc 6 mg)
Trial: 26843086
Drug: MEDI4212 (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI4212 (subcutaneous doses of 5, 15, 60, 150, or 300 mg; intravenous dose of 300 mg)
Trial: 26843086
Drug: Omalizumab (subcutaneous)
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Omalizumab (subcutaneous)
Trial: 21593352
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g l-glutamine (Gln-30)
Trial: 21593352
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g L-glutamine (Gln-15)
Trial: 21593352
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg SIT
Trial: 21593352
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg SIT and 15 g L-glutamine (SIT+Gln-15)
Trial: 19920419
Drug: T2 thermolesion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T2 thermolesion with local application of 0.5 mL of 6% phenol
Trial: 16834836
Drug: Olmesartan 20
RxNorm normalized name: olmesartan 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan 20 mg for 8 weeks
Trial: 16834836
Drug: Olmesartan 20
RxNorm normalized name: olmesartan 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan 20 mg for 12 weeks (controlled patients)
Trial: 15323064
Drug: Olmesartan 20
RxNorm normalized name: olmesartan 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan 20 mg/day
Trial: 16834836
Drug: Olmesartan 40
RxNorm normalized name: HCTZ 25/OLMESARTAN 40MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan 40 mg/day or olmesartan 20 mg/day plus 12.5 mg hydrochlorothiazide for 4 weeks (non-controlled patients)
Trial: 8874573
Drug: Intraarticular morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarticular morphine 5 mg
Trial: 9088813
Drug: Intraarticular morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarticular morphine 1 mg
Trial: 9088813
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 20 mL (Control)
Trial: 21753777
Drug: Exercise program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise program (twice a week for 6 months, emphasizing swimming)
Trial: 20110025
Drug: SAMe 1200
RxNorm normalized name: SAMe
DrugBank: Ademetionine (DB00118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAMe 1200 mg/d (400 mg TID)
Trial: 20110025
Drug: Nabumetone 1000
RxNorm normalized name: nabumetone 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabumetone 1000 mg/d (once daily in the evening)
Trial: 8339409
Drug: Warfarin prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin prophylaxis (adjusted to prolong INR to 1.5 on the day of surgery and 2.5 after surgery)
Trial: 24996842
Drug: Synbiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synbiotic therapy for 6 weeks
Trial: 20038863
Drug: Standard Early
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Early Treatment Diabetic Retinopathy Study focal laser treatment
Trial: 16580904
Drug: Voriconazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voriconazole (400 mg twice daily on the first day and 200 mg twice daily on the second day)
Trial: 9296215
Drug: Molgramostim 5
RxNorm normalized name: molgramostim
DrugBank: Molgramostim (DB12525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molgramostim 5 micrograms/kg every 12 hours for 14 days, given alongside chemotherapy regimens.
Trial: 30606383
Drug: CT angiography
RxNorm normalized name: CT-179
DrugBank: CT-179 (DB17114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT angiography using low-voltage (80 kVp) and low-concentration contrast media (300 mgI/ml) with IMR algorithm
Trial: 30606383
Drug: CT angiography
RxNorm normalized name: CT-179
DrugBank: CT-179 (DB17114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT angiography using regular voltage (100 kVp) and higher concentration contrast media (370 mgI/ml) with hybrid iterative reconstruction technique
Trial: 26907736
Drug: Ledipasvir (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ledipasvir (90 mg) and sofosbuvir (400 mg) once daily plus ribavirin (600‐1200 mg daily) for 12 weeks
Trial: 26907736
Drug: Ledipasvir (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ledipasvir (90 mg) and sofosbuvir (400 mg) once daily plus ribavirin (600‐1200 mg daily) for 24 weeks
Trial: 18366766
Drug: Open-label continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label continuous combined hormone therapy
Trial: 15604942
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with monitoring using (99m)Tc-Sestamibi scintimammography
Trial: 6633596
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of progesterone receptors
Trial: 6633596
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of estrogen receptors
Trial: 6633596
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of estrogen and progesterone receptors
Trial: 29126981
Drug: N-acetyl cysteine
RxNorm normalized name: N-Acetyl Cysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetyl cysteine (NAC) 1200 mg
Trial: 26857782
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg ropivacaine plus 5 μg dexmedetomidine (RD)
Trial: 26857782
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg ropivacaine plus 15 μg fentanyl (RF)
Trial: 26857782
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg ropivacaine (R)
Trial: 19153116
Drug: FOLFIRI-3 (irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI-3 (irinotecan 100 mg/m(2) days 1 and 3 combined with LV 400 mg/m(2) day 1 and 46-h continuous 5-FU 2000 mg/m(2))
Trial: 19153116
Drug: FOLFIRI-1 (irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI-1 (irinotecan 180 mg/m(2) day 1 combined with LV 400 mg/m(2) day 1, 5-FU bolus 400 mg/m(2) and 46-h continuous 5-FU 2400 mg/m(2))
Trial: 15182413
Drug: 1 day
RxNorm normalized name: ZonaCort 11 Day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 day antibiotic prophylaxis (ciprofloxacin or levofloxacin)
Trial: 15182413
Drug: 3 day
RxNorm normalized name: Kathro 3 Day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 day antibiotic prophylaxis (ciprofloxacin or levofloxacin)
Trial: 15182413
Drug: 1 day
RxNorm normalized name: ZonaCort 11 Day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 day antibiotic prophylaxis
Trial: 15182413
Drug: 3 day
RxNorm normalized name: Kathro 3 Day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 day antibiotic prophylaxis
Trial: 12201823
Drug: Non-GH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-GH treatment